Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN-04
2020-004662-19Phase 2Active
- Sponsor
- ALX Oncology
- Start
- Apr 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of evorpacept in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by ALX Oncology. Primary endpoints: 12-month overall survival rate and objective response rate. Started Apr 2021; status: active.
02
Drugs
evorpacept
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2020-004662-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004662-19.